Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

Pediatric Blood and Cancer

Volumn 48, Issue 2, 2007, Pages 132-139

  Wagner, Lars M ^a,f   McAllister, Nancy ^a   Goldsby, Robert E ^a   Rausen, Aaron R ^c   McNall Knapp, René Y ^d   McCarville, M Beth ^e   Albritton, Karen ^a,b  

^a PRIMARY CHILDREN'S MEDICAL CENTER   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Ewing sarcoma; Irinotecan; Peripheral primitive neuroectodermal tumor; Temozolomide

Indexed keywords

CARBOPLATIN; CEFPODOXIME; CYCLOPHOSPHAMIDE; ETOPOSIDE; GENTAMICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; REBECCAMYCIN; TEMOZOLOMIDE; TOPOTECAN; VINCRISTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; EWING SARCOMA; FEMALE; FEVER; HUMAN; INFECTION; LIVER TOXICITY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CAMPTOTHECIN; CHILD; DACARBAZINE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; NEOPLASM METASTASIS; SARCOMA, EWING'S;

EID: 33845618682     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20697     Document Type: Article

References (37)

1. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
2. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-3430.
3. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.
4. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Med Pediatr Oncol 2003;40:276-287.
5. Bacci G, Ferrari S, Longhi A, et al. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 2003;14:1654-1659.
6. Shankar AG, Ashley S, Craft AW, et al. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med Pediatr Oncol 2003;40:141-147.
7. Burdach S, Jurgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 2002;41:169-189.
8. Frohlich B, Ahrens S, Burdach S, et al. High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS. Klin Padiatr 1999;211:284-290.
9. Masuda N, Kudoh S, Fukuoka M. Irinotecan (CPT-11): Pharmacology and clinical applications. Crit Rev Oncol Hematol 1996;24:3-26.
10. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000;6:4110-4118.
11. Houghton PJ, Cheshire PJ, Hallman JD 2nd, et al. Efficacy of topoisomerase 1 inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995;36:393-403.
12. Vassal G, Terrier-Lacombe MJ, Bissery MC, et al. Therapeutic activity of CPT-11, a DNA-topoisomerase 1 inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts. Br J Cancer 1996;74:537-545.
13. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
14. Patel VJ, Elion GB, Houghton PJ, et al. Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin Cancer Res 2000; 6:4154-4157.
15. Donafrancesco A, DeSio L, Milano GM, et al. Temozolomide in resistant or relapsed pediatric solid tumors: A phase II study. Proc Am Soc Clin Oncol 2003;810a.
16. Pourquier P, Waltman JL, Urasaki Y, et al. Topoisomerase 1-mediated cytotoxicity of N-methyl-N′-nitro-N-nitrosoguanidine: Trapping of topoisomerase 1 by the O6-methylguanine. Cancer Res 2001;61:53-58.
17. Stupp R, Ostermann S, Calderoni A, et al. Temozolomide and irinotecan for primary brain tumors: A dose escalation study. Proc Am Soc Clin Oncol 2003;104a.
18. Badruddoja M, Reardon D, Beason R, et al. Phase I study of temozolomide plus irinotean (CPT-11) in adults with recurrent malignant glioma. Proc Am Soc Clin Oncol 2003;102a.
19. Gruber ML, Buster WP. Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma. Am J Clin Oncol 2004;27:33-38.
20. Jones SF, Gian VG, Greco FA, et al. Phase 1. Trial of irinotecan and temozolomide in patients with solid tumors. Oncology (Huntingt) 2003;17:41-45.
21. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840-848.
22. Grier HE. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodennal tumors. Pediatr Clin North Am 1997; 44:991-1004.
23. Sohaib SA, Turner B, Hanson JA, et al. CT assessment of tumour response to treatment: Comparison of linear, cross-sectional and volumetric measures of tumour size. Br J Radiol 2000;73:1178-1184.
24. Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, et al. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995;32:635-641.
25. Warren KE, Patronas N, Aikin AA, et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst 2001;93:1401-1405.
26. Prasad SR, Jhaveri KS, Saini S, et al. CT tumor measurement for therapeutic response assessment: Comparison of unidimensional, bidimensional, and volumetric techniques initial observations. Radiology 2002;225:416-419.
27. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
28. Furman W, Crews K, Daw NC, et al. Cefixime enables further dose escalation or oral irinotecan in pediatric patients with refractory solid tumors. Proc Am Soc Clin Oncol 2003;799a.
29. Thompson J, Zamboni WC, Cheshire PJ, et al. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 1997;3:423-431.
30. Takasuna K, Hagiwara T, Hirohashi M, et al. Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride (CPT-11) in rats. Cancer Res 1996;56:3752-3757.
31. Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003;21:3844-3852.
32. Estlin EJ, Lashford L, Ablett S, et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 1998;78:652-661.
33. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 2001;7:32-37.
34. Mugishima H, Matsunaga T, Yagi K, et al. Phase I study of irinotecan in pediatric patients with malignant solid tumors. J Pediatr Hematol Oncol 2002;24:94-100.
35. Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002;24:101-105.
36. Whelan JS, McTiernan A, Kakouri E, Kilby A. Carboplatin-based chemotherapy for refractory and recurrent Ewing's tumours. Pediatr Blood Cancer 2004;43:237-242.
37. Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19: 3463-3469.